Physicians' Academy for Cardiovascular Education

PCSK9 Inhibition & CV Outcomes: Review of Lipid Targets and Treatment Strategies

Meeting report with video, highlights and slides of PACE-CME symposium held at ESC 2017 in Barcelona, more items to follow...

Summary | PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

August 26, 2017 - Prof. Peter Sever (London, UK)
August 26, 2017 - Prof. Peter Sever (London, UK)

The design of the three major CV outcome trials on PCSK9 inhibitors were explained and the results of the FOURIER trial were discussed in detail.

Summary | PCSK9 inhibition across a wide spectrum of patients: One size fits all?

August 26, 2017 - Prof. Kees Hovingh (Amsterdam, the Netherlands)
August 26, 2017 - Prof. Kees Hovingh (Amsterdam, the Netherlands)

The need for additional therapies to lower LDL-c levels was discussed and subsequently the effect of PCSK9 inhibitors in different studies was explained in several patient populations.

Summary | Understanding new PCSK9 outcome data: From the LDL-c hypothesis to LDL-c causality

August 26, 2017 - Prof. John Chapman (Paris, France)
August 26, 2017 - Prof.  John Chapman (Paris, France)

Prof. Chapman briefly introduced the outcome trials on the two PCSK9 inhibitors evolocumab and alirocumab and explained in more detail the pathophysiology of atherosclerotic CVD.

Meeting Impression | PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies

August 26, 2017 - ESC
August 26, 2017 - ESC

The role of PCSK9 inhibitors as a novel strategy to reduce LDL-c was addressed in this educational program at the ESC Congress 2017 in Barcelona, Spain.

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

10' education - Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017 - Online CME
Lecture by Peter Sever, MD held at symposium on PCSK9 inhibition & Cardiovascular Outcomes:  Review of lipid targets and treatment strategies

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017.

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017
Lecture by Prof Kees Hovingh held at symposium on PCSK9 inhibition & Cardiovascular Outcomes:  Review of lipid targets and treatment strategies

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017

PCSK9 Inhibition & CV Outcomes: Review of Lipid Targets and Treatment Strategies
PCSK9 Inhibition & CV Outcomes: Review of Lipid Targets and Treatment Strategies